PE20171800A1 - Produccion de vectores adeno-asociados de gran tamano - Google Patents

Produccion de vectores adeno-asociados de gran tamano

Info

Publication number
PE20171800A1
PE20171800A1 PE2017001997A PE2017001997A PE20171800A1 PE 20171800 A1 PE20171800 A1 PE 20171800A1 PE 2017001997 A PE2017001997 A PE 2017001997A PE 2017001997 A PE2017001997 A PE 2017001997A PE 20171800 A1 PE20171800 A1 PE 20171800A1
Authority
PE
Peru
Prior art keywords
adeno
aav
production
big size
associated vectors
Prior art date
Application number
PE2017001997A
Other languages
English (en)
Spanish (es)
Inventor
Sirkka Kyostio-Moore
David Souza
Karen Vincent
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56943906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171800(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PE20171800A1 publication Critical patent/PE20171800A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PE2017001997A 2015-04-08 2016-04-07 Produccion de vectores adeno-asociados de gran tamano PE20171800A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562144862P 2015-04-08 2015-04-08
US201562220067P 2015-09-17 2015-09-17

Publications (1)

Publication Number Publication Date
PE20171800A1 true PE20171800A1 (es) 2017-12-28

Family

ID=56943906

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001997A PE20171800A1 (es) 2015-04-08 2016-04-07 Produccion de vectores adeno-asociados de gran tamano

Country Status (27)

Country Link
US (1) US10815497B2 (enExample)
EP (2) EP3280799B1 (enExample)
JP (3) JP6878299B2 (enExample)
KR (2) KR102848324B1 (enExample)
CN (1) CN107864657A (enExample)
AU (3) AU2016245806A1 (enExample)
BR (1) BR112017021505A2 (enExample)
CA (1) CA2982123A1 (enExample)
CL (1) CL2017002537A1 (enExample)
CO (1) CO2017011344A2 (enExample)
CR (1) CR20170505A (enExample)
DK (1) DK3280799T3 (enExample)
EA (1) EA201792236A1 (enExample)
EC (1) ECSP17074016A (enExample)
ES (1) ES3008382T3 (enExample)
GT (1) GT201700214A (enExample)
HU (1) HUE069779T2 (enExample)
IL (3) IL294965A (enExample)
MX (1) MX2017012935A (enExample)
PE (1) PE20171800A1 (enExample)
PH (1) PH12017501836A1 (enExample)
PL (1) PL3280799T3 (enExample)
SG (3) SG11201708203UA (enExample)
TN (1) TN2017000431A1 (enExample)
TW (1) TWI707951B (enExample)
UY (1) UY36611A (enExample)
WO (1) WO2016164609A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE063051T2 (hu) 2013-02-15 2023-12-28 Bioverativ Therapeutics Inc Optimalizált VIII. faktor gén
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
WO2016073693A2 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
CA2975583A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Modulatory polynucleotides
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
TWI707951B (zh) * 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
TWI756185B (zh) 2015-09-24 2022-03-01 美商拜奧馬林製藥公司 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物
ES2926585T3 (es) 2016-02-01 2022-10-27 Bioverativ Therapeutics Inc Genes de Factor VIII optimizados
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
SG11201809643UA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
IL262784B2 (en) 2016-05-18 2023-10-01 Voyager Therapeutics Inc modulatory polynucleotides
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11518991B2 (en) 2017-02-24 2022-12-06 Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated RASAL1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including RASAL1 in a subject
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
WO2018204786A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
AU2018269050A1 (en) 2017-05-19 2020-01-16 Encoded Therapeutics, Inc. High activity regulatory elements
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
AU2018311069A1 (en) 2017-08-03 2020-02-20 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
JP7374883B2 (ja) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子およびその使用
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
CN118345115A (zh) 2017-12-01 2024-07-16 编码治疗公司 工程化的dna结合蛋白
EP3794126A1 (en) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for the treatment of parkinson's disease
EP3824095A4 (en) * 2018-07-20 2022-04-20 University of Utah Research Foundation GENE THERAPY FOR MACULATE GENERATION
MX2021001599A (es) 2018-08-09 2021-07-02 Bioverativ Therapeutics Inc Moleculas de acido nucleico y sus usos para la terapia genica no viral.
SG11202103151RA (en) 2018-09-28 2021-04-29 Voyager Therapeutics Inc Frataxin expression constructs having engineered promoters and methods of use thereof
EP3863662A1 (en) * 2018-10-12 2021-08-18 Genzyme Corporation Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
EP4022097A4 (en) * 2019-08-29 2022-12-14 Siemens Healthcare Diagnostics Inc. REAGENTS AND METHODS FOR DETECTING AAV EXCRETION
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
CN111218446B (zh) * 2019-12-25 2023-03-28 劲帆生物医药科技（武汉）有限公司 一种肝脏特异性启动子及其应用
IL296509A (en) * 2020-03-16 2022-11-01 Univ North Carolina Chapel Hill Compositions and methods for the selective detection of tumor-derived viral dna
BR112022026127A2 (pt) 2020-06-24 2023-01-17 Bioverativ Therapeutics Inc Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
AU2021319208A1 (en) 2020-07-30 2023-03-02 Shape Therapeutics Inc. Stable cell lines for inducible production of rAAV virions
JP2023538666A (ja) 2020-08-23 2023-09-08 バイオベラティブ セラピューティクス インコーポレイテッド 閉端ＤＮＡ（ｃｅＤＮＡ）の改善された製造のための改変バキュロウイルス系
CA3229345A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Closed-end dna production with inverted terminal repeat sequences
AR126846A1 (es) 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc Genes del factor viii optimizados
CA3229668A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Baculovirus expression system
IL311725A (en) 2021-09-30 2024-05-01 Bioverativ Therapeutics Inc Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity
MX2024004647A (es) 2021-10-18 2024-05-02 Regeneron Pharma Celulas eucariotas que comprenden polinucleotidos de virus asociados a adenovirus.
AR132545A1 (es) * 2023-04-26 2025-07-16 Sanofi Sa Líneas celulares hospedadoras y métodos para identificar y usar dichas líneas celulares hospedadoras

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
EP2369002A1 (en) 1999-08-09 2011-09-28 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs
EP1224312A1 (en) * 1999-10-12 2002-07-24 The University of North Carolina at Chapel Hill Adeno-associated virus vectors encoding factor viii and methods of using the same
ES2256265T3 (es) 2000-06-01 2006-07-16 University Of North Carolina At Chapel Hill Vectores de parvovirus duplicados.
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
NZ618298A (en) 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
US20040092008A1 (en) * 2002-11-12 2004-05-13 Snyder Richard O. Recombinant AAV vectors for gene therapy of hemophilia A
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
PT1625210E (pt) 2003-05-21 2011-03-15 Genzyme Corp Métodos para produzir preparações de vírions de aav recombinantes substancialmente livres de capsídeos vazios
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
HUE054940T2 (hu) 2009-06-16 2021-10-28 Genzyme Corp Javított eljárások rekombináns AAV-vektorok tisztítására
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
SG10201601110VA (en) 2011-02-17 2016-03-30 Univ Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
DK2911687T3 (da) * 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
SMT202000458T1 (it) * 2013-09-12 2020-11-10 Biomarin Pharm Inc Vettori aav comprendenti un gene codificante il fattore viii
PT3137497T (pt) 2014-05-02 2021-07-12 Genzyme Corp Vetores de aav para terapia genética na retina e snc
LT3256594T (lt) 2015-02-10 2022-02-10 Genzyme Corporation Patobulintas virusinių dalelių tiekimas į dryžuotąjį kūną ir smegenų žievę
TWI707951B (zh) * 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造

Also Published As

Publication number Publication date
SG10201912912QA (en) 2020-02-27
HUE069779T2 (hu) 2025-04-28
AU2022203942B2 (en) 2023-12-14
NZ774736A (en) 2024-08-30
EP3280799B1 (en) 2024-10-30
WO2016164609A2 (en) 2016-10-13
IL283291B (en) 2022-08-01
AU2024201619A1 (en) 2024-03-28
US20190048362A1 (en) 2019-02-14
CN107864657A (zh) 2018-03-30
CL2017002537A1 (es) 2018-05-11
TWI707951B (zh) 2020-10-21
PL3280799T3 (pl) 2025-04-14
PH12017501836A1 (en) 2018-04-23
WO2016164609A3 (en) 2016-12-15
EP4512429A2 (en) 2025-02-26
US10815497B2 (en) 2020-10-27
EP3280799A2 (en) 2018-02-14
ES3008382T3 (en) 2025-03-24
CA2982123A1 (en) 2016-10-13
HK1246339A1 (en) 2018-09-07
ECSP17074016A (es) 2018-02-28
KR20170133500A (ko) 2017-12-05
IL254933B (en) 2021-06-30
KR102848324B1 (ko) 2025-08-20
GT201700214A (es) 2018-10-24
JP2018510648A (ja) 2018-04-19
EP4512429A3 (en) 2025-05-21
AU2016245806A1 (en) 2017-11-30
AU2022203942A1 (en) 2022-06-23
IL283291A (en) 2021-07-29
TW201710498A (zh) 2017-03-16
MX2017012935A (es) 2018-02-12
TN2017000431A1 (en) 2019-04-12
CO2017011344A2 (es) 2018-03-28
IL254933A0 (en) 2017-12-31
JP6878299B2 (ja) 2021-05-26
UY36611A (es) 2016-11-30
BR112017021505A2 (pt) 2018-07-03
IL294965A (en) 2022-09-01
JP2021118724A (ja) 2021-08-12
KR20250126875A (ko) 2025-08-25
EA201792236A1 (ru) 2018-03-30
SG11201708203UA (en) 2017-11-29
NZ737009A (en) 2024-01-26
SG10201909381WA (en) 2019-11-28
CR20170505A (es) 2018-01-26
JP2023116678A (ja) 2023-08-22
DK3280799T3 (da) 2025-01-27

Similar Documents

Publication Publication Date Title
PE20171800A1 (es) Produccion de vectores adeno-asociados de gran tamano
Zhao et al. Recent progress in shape memory polymer: New behavior, enabling materials, and mechanistic understanding
IL285060B (en) Enhanced delivery of viral particles to the striatum and cortex
IL323969A (en) Methods for determining serotype and heterogeneity of a viral particle and improving its stability
SG11201702073XA (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
Proinov General convergence theorems for iterative processes and applications to the Weierstrass root-finding method
MX395524B (es) Proteinas de cápside modificadas para un suministro mejorado de vectores de parvovirus.
MX2016010649A (es) Vector de virus adeno-asociado.
EP3177720A4 (en) Virus like particle comprising modified envelope protein e3
IL251532A0 (en) Modified virus-like particles of cmv
EP3262162A4 (en) Regulatable expression using adeno-associated virus (aav)
Naumann et al. On the thermodynamics of pseudo-elastic material models which reproduce the Mullins effect
ZA201802117B (en) Canine parvovirus (cpv) virus¿like particle (vlp) vaccines and uses thereof
MX2016006167A (es) Metodos para la inactivacion viral usando detergentes ecologico.
MX384795B (es) Vectores que comprenden secuencias de polinucleotidos rellenadoras/de relleno y metodos de uso.
JP2017528075A5 (enExample)
Gabriyelyan Bounded subgroups as a von Neumann radical of an Abelian group
EP3545083A4 (en) Vaccines against infectious diseases caused by positive stranded rna viruses
HUE049890T2 (hu) Rekombináns bõrcsomósodáskór vírus kiütött mutáns és annak alkalmazásai
JP2017535495A5 (enExample)
Bianchi et al. Some advances on the set covering polyhedron of circulant matrices
AR104216A1 (es) Producción de vectores adeno-asociados de gran tamaño
JP2015062178A5 (enExample)
HK1254487A1 (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
EP3014624A4 (en) ARRANGEMENT OF VERTICALLY ORIENTED NANOTEEL ARRAYS WITH PARTICLES AND USE THEREOF